Work Here?
Overview
Pharmathen develops generic medicines and advanced drug-delivery technologies from its Greece-based manufacturing sites, exporting to branded pharmaceutical companies and patients worldwide. Its products include long-acting injectables, sustained-release formulations, and ophthalmic drugs, built on a strategy of Life Cycle Management and new technology platforms. The company operates with full vertical integration, handling research, development, manufacturing, and export, under facilities approved by the US FDA and EU. This enables it to deliver high-quality generic solutions and optimized dosage forms at scale. Pharmathen differentiates itself through a focused emphasis on drug-delivery platforms, continuous pipeline development, and end-to-end control over development and manufacturing. Its goal is to provide high-quality, affordable medicines while expanding its capabilities in innovative generic products and advanced delivery technologies for global markets.
About Pharmathen
Industries
Industrial & Manufacturing
Healthcare
Company Size
501-1,000
Company Stage
Acquired
Total Funding
N/A
Headquarters
Athens, Greece
Founded
1969
Get referred to Pharmathen
See people who can refer or advise you
Simplify's Take
What believers are saying
- Neuraxpharm and Pharmathen launched 2024 psychiatry LAIs, expanding LATT commercialization.
- Partners Group injected €130 million in November 2025, signaling continued lender support.
- Pharmathen still serves over 215 generic customers across 85 countries.
What critics are saying
- FDA issued an import alert on April 23, 2026 for Pharmathen International.
- June 2026 warning letter cited sterility, data-integrity, and CAPA failures at Sapes.
- US market shutdown can strand Pharmathen's debt and force a distressed sale.
What makes Pharmathen unique
- Pharmathen pairs LAI, sustained-release, and ophthalmic platform development with FDA-approved Greek manufacturing.
- CBL Patras added vertically integrated peptide manufacturing and US-FDA-approved supply capabilities.
- Neuraxpharm's 2024 alliance gives Pharmathen exclusive North America rights for psychiatry LAIs.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$0
Below
Industry Average
Funded Over
1 Rounds
Benefits
Health Insurance
Training Programs
Growth & Insights and Company News
6 month growth
↑ 14%1 year growth
↑ 14%2 year growth
↑ 14%NTC, an Italian pharmaceutical company specialising in ophthalmology, has completed the acquisition of Pharmathen's ophthalmology business unit with support from its main shareholder Wise Equity. The deal adds a consolidated portfolio of glaucoma treatments to NTC's offerings. The acquisition brings NTC's revenue to approximately €100 million, with over 80% derived from ophthalmology. The company now reaches more than 100 countries through over 250 distribution partners and gains entry into the US market through its B2B model. The acquired glaucoma portfolio includes many preservative-free formulations and complements NTC's existing therapeutic areas covering antibiotic therapy, inflammation, allergies and dry eye. Globally, around 80 million people suffer from glaucoma, a number expected to reach 112 million by 2040. Wise Equity's Wisequity VI fund, launched in May 2023 with €400 million in commitments, supported the transaction.
Neuraxpharm and Pharmathen have signed a co-development agreement to develop long-acting injectable (LAI) therapies for the psychiatry sector.
New therapies will allow patients greater choice and flexibility in the control of CNS disorders. BARCELONA, Spain, DÜSSELDORF, Germany, and ATHENS, Greece, Dec. 12, 2024 /PRNewswire/ -- Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, and Pharmathen, one of the largest pharmaceutical companies in Greece and leaders in the development and supply of long-acting injectable (LAI) therapies, announce a strategic alliance to co-develop new long-acting injectable therapies within the psychiatry field under Pharmathen's long-acting therapeutic technologies (LATT) program. Under this agreement, Neuraxpharm will have exclusive rights to commercialise these therapies in Europe, and in countries outside of Europe where the group has a direct presence, while Pharmathen will have exclusive rights for North America and all other countries not covered by Neuraxpharm
The buyout fund bought Greece-based generics manufacturer Pharmathen in 2021 for €1.6bn including debt and last year invested alongside GHO in drug manufacturing outsourcer Sterling Pharma Solutions.
Ropes & Gray has advised Pharmathen, a leading European complex drug delivery and formulation developer, on its acquisition of CBL Patras, a leading vertically integrated and US-FDA approved peptide manufacturer and supplier in Europe.
There are no jobs for Pharmathen right now.
Find jobs on Simplify and start your career today
About Pharmathen
Industries
Industrial & Manufacturing
Healthcare
Company Size
501-1,000
Company Stage
Acquired
Total Funding
N/A
Headquarters
Athens, Greece
Founded
1969
There are no jobs for Pharmathen right now.
Find jobs on Simplify and start your career today